Martin Dreyling, MD

Martin Dreyling, MD, discusses the next steps for research with ibrutinib in the mantle cell lymphoma space following the presentation of data from the phase 3 TRIANGLE study.

Martin Dreyling, MD, discusses the outcomes of the phase 3 TRIANGLE study evaluating ibrutinib in patients with mantle cell lymphoma.

Martin Dreyling, MD, discusses findings from the phase 3 TRIANGLE study of ibrutinib in patients with mantle cell lymphoma.

Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.